Description
Indication & Scope
KeTaiLai® Tagitanlimab Injection treats recurrent or metastatic nasopharyngeal carcinoma.
- Mechanism: Anti-PD-1 immune checkpoint inhibitor, blocks PD-1/PD-L1 binding to reactivate tumor-specific T lymphocytes and enhance anti-tumor immune response.
- Drug class: PD-1 inhibitor immune checkpoint monoclonal antibody, anti-tumor immunotherapy agent.
- Clinical use: Systemic immunotherapy for recurrent and metastatic nasopharyngeal carcinoma.
| Generic Name | Tagitanlimab Injection |
| Brand Name | KeTaiLai |
| Ingredient | Tagitanlimab Injection |
| Dosage Form | Injection |
| Package | 200mg(10ml)*1 vial |
| Conditions Treated | Recurrent or metastatic nasopharyngeal carcinoma |
| Taboos | Active autoimmune diseases requiring long-term immunosuppression, severe hypersensitivity to monoclonal antibody products, organ transplant recipients, uncontrolled severe infections, pregnant and breastfeeding women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store undiluted solution at 2°C~8°C, light protection, avoid freezing |
| Manufacturer | KeLunTaiBo Bioparmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20240058 |
| Approval Date | Dec 25, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Fixed dose administered per 2-week treatment cycle.
Time: Intravenous infusion repeated every 2 weeks for continuous tumor treatment.
Instructions for use: Dilute to specified concentration, deliver via controlled-rate intravenous infusion.
Interaction: Systemic high-dose corticosteroids and immunosuppressants reduce therapeutic efficacy and raise immune-related adverse event risks.
Side effects: Immune-related thyroid dysfunction, fatigue, rash, infusion reactions, pneumonitis, anemia.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What cancer does Tagitanlimab Injection treat?
It is used for the treatment of recurrent or metastatic nasopharyngeal carcinoma.
What is the pharmacological classification of Tagitanlimab Injection?
It is a PD-1 immune checkpoint inhibitor monoclonal antibody for tumor immunotherapy.
How does Tagitanlimab Injection exert anti-tumor effects?
It blocks PD-1/PD-L1 binding to reactivate inhibited T cells and restore anti-tumor immune function.
What patients are prohibited from using Tagitanlimab Injection?
Patients with active autoimmune diseases, organ transplantation history and uncontrolled severe infections are contraindicated.
KeTaiLai® | Tagitanlimab Injection | NPC | DengYueRX
INN: Tagitanlimab Injection
Indications: Nasopharyngeal carcinoma(NPC)
Dosage Form: Injection
Strength: 200mg(10ml)/vial
